An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Owlet Announces UK Medical Certification of Dream Sock®
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Owlet, a leader in smart infant monitoring, has achieved UKCA certification for its Dream Sock, a significant milestone following its recent CE Mark certification. This recognition allows Owlet to expand its reach across the UK and Europe, where it already has key retail partnerships. The Dream Sock, designed for healthy infants, measures oxygen saturation, pulse rate, and provides sleep insights. It will soon be available at major retailers in the UK, Germany, and France, and later in other European countries. This expansion is poised to impact over 3.8 million annual births in the region.
Positive
Owlet received UKCA certification for Dream Sock, facilitating market expansion.
Recent CE Mark certification complements UKCA, strengthening market position.
FDA marketing authorizations in the US for Dream Sock and BabySat reinforce product credibility.
Key retail partnerships across Europe enhance product accessibility.
Potential market reach increase with over 3.8 million annual births in Europe.
Dream Sock offers clinically-proven accuracy and modern connectivity through the Owlet Dream App.
Negative
No direct revenue figures or financial impact discussed in the PR.
Potential market risks if certifications do not translate into expected sales.
Insights
The certification of Owlet’s Dream Sock in the UK represents an important expansion opportunity for the company. With the UKCA certification, Owlet can now enter new markets and potentially increase its revenue streams. Given that 3.8 million babies are born in Europe annually, this move could significantly grow Owlet’s customer base. Effective market penetration will depend on their ability to form strong partnerships with retailers and optimize their marketing strategy to resonate with European consumers. Retail investors should watch closely for updates on retail partnerships and sales performance in these new markets.
The UKCA certification follows Owlet’s previous CE mark certification and FDA approval, illustrating a robust regulatory pathway for their products. The Dream Sock’s medical-grade technology has been validated for use in multiple major regions, which is a testament to its reliability and accuracy. From a medical perspective, the ability to monitor oxygen saturation and pulse rate in infants offers peace of mind for parents and caregivers. However, it’s important to note that the device is meant to supplement—not replace—traditional medical supervision. Investors should consider the broader implications of regulatory approvals as they often indicate product quality and reliability.
The strategic importance of the UKCA certification should not be underestimated. It opens up substantial new revenue channels across Europe, especially in key markets like the UK, Germany and France. Retail investors should note that expanding into these markets can lead to significant revenue growth, but it will also involve marketing and distribution costs. Analyzing quarterly earnings post-expansion will be important to understand the financial implications fully. This certification also positions Owlet to leverage their previous FDA approval to potentially introduce more products globally, which could diversify and stabilize their revenue streams.
Parents in the United Kingdom will soon have access to Owlet’s Dream Sock with UKCA certification
LEHI, Utah--(BUSINESS WIRE)--
Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, has received UK medical device certification, following the recent achievement of CE Mark certification. This marks a significant milestone for Owlet, moving the company forward in its mission to increase access to medical-grade infant monitoring technology to parents and caregivers around the world.
The UKCA certification, granted by a recognized UK-approved body, follows the recent announcement of Owlet’s EU CE mark certification of Dream Sock earlier this month and now provides Owlet with medical device certifications in key UK and European markets where its distribution partners operate. These certifications also follow the Company’s marketing authorizations from the U.S. Food and Drug Administration (the “FDA”), for Dream Sock, with new medical technology for healthy infants over-the-counter without a prescription, and for BabySat®, a prescription-only pulse oximeter designed for use with babies that have a pre-existing medical condition.
“With the addition of the UKCA certification, Owlet is now able to increase its reach throughout the European market, where more than 3.8 million babies are born each year1. This represents a significant opportunity for Owlet to expand its business and reach more families with its innovative baby monitoring products,” said Jonathan Harris, Owlet President and Chief Revenue Officer. “Owlet is extremely well-positioned to take advantage of both the UKCA and EU medical certifications with key retail partnerships across the European market. These partnerships will allow the Company to reach a wider range of consumers and make its products more accessible to families in the region.”
Dream Sock comfortably wraps around a baby's foot and is intended for routine, in-home surveillance of healthy infants by measuring oxygen saturation and pulse rate, and will provide sleep insights for parents that are new for the UK market. Its advanced technology offers clinically-proven accuracy, while the connected Owlet Dream App delivers live readings directly to a mobile device and a nearby Base Station – both of which can provide a notification to the caregiver, prompting them to assess the infant. Dream Sock, as certified for the UK, is intended for use with healthy infants between 0-18 months and 2.5-13.6 kg. Its notifications and associated data are intended to supplement the decision by caregivers to seek additional guidance for medical care of the infant. It is not intended to replace traditional methods of diagnosis and/or treatment.
Owlet’s Dream Sock is expected to launch at major retailers in the UK, Germany, and France in the coming months, with other European countries to follow later this summer at www.owletbabycare.co.uk and Amazon in select markets.
About Owlet, Inc.
Owlet’s digital health infant monitoring platform is transforming the journey of parenting. The Company (NYSE:OWLT), a small-cap healthcare growth equity, offers FDA-authorized medical and consumer pediatric wearables and an integrated HD visual and audio camera that provide real-time data and insights to parents who safeguard health, optimize wellness, and ensure peaceful sleep for their children.
Since 2012, over 2 million parents worldwide have used Owlet’s platform contributing to one of the largest collections of consumer infant health and sleep data. The Company continues to develop software and digital data solutions to bridge the current healthcare gap between hospital and home and bring new insights to parents and caregivers globally. Owlet believes that every child deserves to live a long, happy, and healthy life. To learn more, visit www.owletcare.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s certification of its Dream Sock in the UK and the impacts, growth prospects, and expanded product offerings and product availability in international markets. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made and are susceptible to a number of risks, uncertainties and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by our forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the availability of, adoption and commercial success of Dream Sock and its new medical technology within these international markets, (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for our products and other regulatory requirements and legal proceedings; (iii) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (iv) the Company’s ability to enhance future operating and financial results or obtain additional financing to continue as a going concern; (v) Owlet’s ability to obtain additional financing in the future, as well risks associated with the Company’s current loan and debt agreements, including compliance with debt covenants, restrictions on the Company’s access to capital, the impact of the Company’s overall debt levels and the Company’s ability to generate sufficient future cash flows to meet Owlet’s debt service obligations and operate Owlet’s business; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (vii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements, including but not limited to requirements concerning privacy and data protection, breaches and loss, as well as other risks associated with Owlet’s digital platforms and technologies; (viii) Owlet’s ability to maintain relationships with customers, manufacturers and suppliers and retain Owlet’s management and key employees; (ix) Owlet’s ability to upgrade and maintain its information technology systems; (x) changes in applicable laws or regulations; (xi) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control, such as health epidemics or pandemics, macro-economic uncertainties, social unrest, hostilities, natural disasters or other catastrophic events; (xii) the possibility that Owlet may be adversely affected by other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xiii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and the Company can't predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
